Evidence map›Paper›PMID 28356569›Full record

ArticleImmunology and cell biology2017

Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8

Hung-Chang Chen, Noémie Joalland, John S Bridgeman, Fouad S Alchami, Ulrich Jarry, Mohd Wajid A Khan, Luke Piggott, Yasmin Shanneik, Jianqiang Li, Marco J Herold and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunology and cell biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Targeting Breast Cancer Stem Cells.International journal of biological sciences · 2023
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 5 countries.

Hung-Chang ChenDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Noémie JoallandINSERM, Unité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.
John S BridgemanDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Fouad S AlchamiCardiff and Vale University Health Board, University Hospital of Wales, Cardiff, UK.
Ulrich JarryINSERM, Unité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.
Mohd Wajid A KhanDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Luke PiggottDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Yasmin ShanneikDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Jianqiang LiInstitute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
Marco J HeroldInstitute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
Thomas HerrmannInstitute for Virology and Immunobiology, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
David A PriceDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Awen M GallimoreDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Richard W ClarksonSchool of Biosciences, Cardiff University, Cardiff, UK.
Emmanuel ScotetINSERM, Unité Mixte de Recherche 892, Centre de Recherche en Cancérologie Nantes Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.
Bernhard MoserDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Matthias EberlDivision of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK.ORCID 0000-0002-9390-5348
Institute of Infection and Immunity · CACardiff University · GBInserm · FRUniversity of Würzburg · DECardiff and Vale University Health Board · GBCentre National de la Recherche Scientifique · FRWalter and Eliza Hall Institute of Medical Research · AU

Funding

Cancer Research UK 13823Cancer Research UK 21200Cancer Research UK C16731/A21200Cancer Research UK C28524/A9497Cancer Research UK C42921/A13823Department of Health II-LA-0712-20006Medical Research Council MR/L018284/1Medical Research Council MR/N023145/1Wellcome TrustWellcome Trust 100326/Z/12/Z
6 · The paper itself

Abstract

The inherent resistance of cancer stem cells (CSCs) to existing therapies has largely hampered the development of effective treatments for advanced malignancy. To help develop novel immunotherapy approaches that efficiently target CSCs, an experimental model allowing reliable distinction of CSCs and non-CSCs was set up to study their interaction with non-MHC-restricted γδ T cells and antigen-specific CD8

Indexed as

AnimalsAntibodiesBreastBreast NeoplasmsCD8-Positive T-LymphocytesCytotoxicity, ImmunologicDiphosphonatesEpithelial CellsEpitopesFemaleHumansImidazolesImmunity, InnateInterferon-gammaMajor Histocompatibility ComplexMiceAntibodiesDiphosphonatesEpitopesImidazolesInterferon-gammaras ProteinsReceptors, Antigen, T-Cell, gamma-deltaZoledronic Acid

Identifiers

PMID28356569
PMCPMC5550559
OpenAlexW2598349249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.